Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

285

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

September 7, 2025

Study Completion Date

November 15, 2025

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

PM1003 Injection

Subjects will receive PM1003 by intravenous administration.

Trial Locations (2)

RECRUITING

Cancer Hospital Affiliated to Shandong First Medical University, Jinan

RECRUITING

Shanghai Orient Hospital, Shanghai